{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1000"},{"groupId":"OG001","value":"1000"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients who failed a prior treatment with dose-intense melphalan","groups":[{"description":"Phase 1 Dose Level 600, 800, 1000 mg of Thalidomide","id":"OG000","title":"Phase 1"},{"description":"Phase 2 Dose Level 1000 mg of Thalidomide","id":"OG001","title":"Phase 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Dose escalation will be based on the assessment of tolerability determined after the last patient of each cohort reaches day +21.","title":"Maximum Tolerated Dose of Thalidomide","type":"PRIMARY","unitOfMeasure":"mg"}